AUTHOR=Childers Martin K., Bogan Janet R., Bogan Daniel J., Greiner Hansel , Holder Melanie , Grange Robert , Kornegay Joe N. TITLE=Chronic Administration of a Leupeptin-Derived Calpain Inhibitor Fails to Ameliorate Severe Muscle Pathology in a Canine Model of Duchenne Muscular Dystrophy JOURNAL=Frontiers in Pharmacology VOLUME=2 YEAR=2012 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2011.00089 DOI=10.3389/fphar.2011.00089 ISSN=1663-9812 ABSTRACT=
Calpains likely play a role in the pathogenesis of Duchenne muscular dystrophy (DMD). Accordingly, calpain inhibition may provide therapeutic benefit to DMD patients. In the present study, we sought to measure benefit from administration of a novel calpain inhibitor, C101, in a canine muscular dystrophy model. Specifically, we tested the hypothesis that treatment with C101 mitigates progressive weakness and severe muscle pathology observed in young dogs with golden retriever muscular dystrophy (GRMD). Young (6-week-old) GRMD dogs were treated daily with either C101 (17 mg/kg twice daily oral dose,